Skip to main content

Biologics

Clinical Trial Boom or Bust in Severe COVID-19

Oct 20, 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease.

Dr. John Cush RheumNow ( View Tweet)

Oct 19, 2020
SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

Oct 19, 2020

TNF Inhibitors or non-TNF Biologics - First Best Choice?

Oct 18, 2020

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and

Read Article

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

Oct 15, 2020

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer

Read Article

ICI Arthritis Tied to Cancer Progression

Oct 14, 2020

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.



Almost 90% of patients treated with ICI develop immune-related adverse events, which can include pulmonary,

Read Article

Tofacitinib and Thromboembolic Risk

Oct 13, 2020

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (

Read Article

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Oct 08, 2020

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Biologics Beneficial in Eosinophilic Vasculitis

Oct 08, 2020

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.



Among 63 patients who were treated with rituximab (Rituxan), remission or partial responses at 1 year were observed

Read Article

Sustained Remission Off Therapy Unlikely in GPA

Oct 08, 2020

A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.

Read Article
Study of 222 RA pts on MTX given anti-GMCSF (otilimab) 22·5 mg, 45 mg, 90 mg, 135 mg, 180 mg, or PBO weekly x 5 wks, then EOW. @wk 24 DAS28-CRP <2·6 5%, 16%. 19%, 14%, 14% respectively and 3% in PBO. Otilimab failed to meet primary endpoint.

Dr. John Cush RheumNow ( View Tweet)

Oct 08, 2020

IL-1 Inhibition Alters Arthroplasty Rates

Oct 07, 2020

A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.

Read Article
European collaborative study of eosinophilic granulomatosis with polyangiitis (EGPA) Rx w/ RTX, mepolizumab or omalizumab (OMA). MEP > RTX > OMA. Mepolizumab was highly effective in GC‐dependent asthma. https://t.co/fi8pjnJO03

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Utilization study of 1031 tofacitinib vs 17,803 biologic DMARD Rx-patients shows 14% higher discontinuations w/ TOFA (HR 1.14), but pts who switched to tofacitinib from a bDMARD had longer persistence than pts switched to another bDMARD (HR 0.90) https://t.co/5cqloT

Dr. John Cush RheumNow ( View Tweet)

Oct 05, 2020
Latest data Global Rheumatology Alliance COVID Registry -2121 pts (40% RA, 17% SLE, 9% PsA), 64% on DMARDs, 33% biologics, 5% JAKi, 34% steroid,27% HCQ, with only 7.6 deaths and 39% hospitalized and 81% resolved infection. https://t.co/g0w4QZHmRl

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020

Defining Difficult Rheumatoid Arthritis

Oct 01, 2020

‘Difficult-to-treat RA’ is an oft-used term that carries various clinical qualities and therapeutic disappointments. A EULAR Task Force was established to develop recommendations for the management of difficult-to-treat rheumatoid arthritis and as a first step, have put forth their definition of

Read Article

Low Risk of Latent TB with Secukinumab

Oct 01, 2020

TB reactivation and latent tuberculosis infection (LTBI) are warned against with biologic agents, especially TNF inhibitors; yet clinical trial data now shows that the risk of LTBI with IL-17 inhibition via secukinumab is uncommon.

Read Article

Slow Lung Decline Typical in Systemic Sclerosis

Sep 30, 2020

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database

Read Article
388 RA pts Rx w/ either b/tsDMARD (Group I) or csDMARD (Group II) . After 3 years, BMD stable at the femoral neck, hip and lumbar (L1–4) (P =0.09, 0.15, 0.87) in Group I, but .

Dr. John Cush RheumNow ( View Tweet)

Sep 30, 2020

Novel Biologic Promising in Mid-Stage Scleroderma Trial

Sep 29, 2020

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.



At week 24, the least squares mean change from baseline on the modified Rodnan skin score was -4.76 for patients

Read Article

Filgotinib Approved by the EMA for Rheumatoid Arthritis

Sep 27, 2020

On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded

Read Article

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article

EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management

Sep 24, 2020

In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.



This guideline committee included 28

Read Article
×